Technoderma Medicines, Inc., a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing in its Phase 1b (MAD) clinical trial of topical TDM-105795 solution in patients with Androgenetic Alopecia (AGA).
Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun recruitment for its second Phase 1 clinical trial of topical TDM-105795 in patients with Androgenetic Alopecia (AGA).
TechnoDerma has recently announced the appointment of Ms. Lu Jiandong as the Chief Financial Officer of the Company.
TechnoDerma announced the appointment of key members of the Scientific Advisory Board, Professor Xiang Leihong, a dermatologist at Fudan University School of medicine, Dr. John Mao, a senior drug R & D expert in the San Francisco Bay area, Professor G
TDM-105795 is the Lead Small Molecule Drug in Topical Formulation
TechonoDerma is an innovation-oriented R&D biotech focusing on the development of novel small molecule drugs for dermatological conditions. Located in Jiaxing Xiuzhou Biopharmaceutical National Park, TechnoDerma has been designated as a leading enterprise by the Jiaxing Municipal Government of Zhejiang Province.
The company's current R&D pipeline includes candidate drugs for hair loss, atopic dermatitis, psoriasis, and systemic lupus erythematosus (SLE). TechnoDerma's first and the most advanced research and development program is the first-in-class small molecule drug candidate TDM-105795 for the treatment of androgenetic alopecia (AGA), which has been granted global intellectual property rights. In addition, TechnoDerma has several ongoing programs for the treatment of psoriasis and atopic dermatitis.
